Cresilon Announces Poster Presentation on TRAUMAGEL Case Study at the 2025 Military Health System Research Symposium

NEW YORK, Aug. 4, 2025 /PRNewswire/ -- Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced that a case study demonstrating the clinical use of its FDA-cleared hemostatic medical device, TRAUMAGEL®, in an emergency hemorrhagic trauma setting has been selected for a poster presentation at the 2025 Military Health System Research Symposium (MHSRS) taking place August 4-7 in Kissimmee, Florida.

Details of Cresilon's presentation are as follows:

• Poster: A Case Study Demonstrating the Utility of TRAUMAGEL® in Emergency Hemorrhagic Trauma Setting
• Abstract ID: MHSRS-25-15025
• Presenter: Dr. Dhanushka Vitharana, M.D., Louisiana State University Health Science Center
• Session Title: Hemorrhage Control and Vascular Dysfunction
• Date and Time: Tuesday, August 5, 3:30-5:30 p.m. EDT
• Location: Gaylord Palms Resort and Convention Center

Cresilon representatives will be available to talk about how TRAUMAGEL can be easily deployed to control bleeding in seconds across emergency response and military environments at the poster session and at Booth #1013. A copy of the poster presentation will be available on Cresilon's website after the conclusion of the conference at https://cresilon.com/traumagel/.

The MHSRS is the Department of Defense's foremost scientific meeting. It provides a venue for presenting new scientific knowledge resulting from military-unique research and development. The MHSRS is the premier military or civilian meeting that focuses specifically on the unique medical needs of the Warfighter. The MHSRS provides a collaborative setting for the exchange of information between military providers with deployment experience, research and academic scientists, international partners, and industry on research and related health care initiatives.

About Cresilon
Cresilon® is a Brooklyn-based biotechnology company that develops, manufactures, and markets hemostatic medical devices utilizing the company's proprietary hydrogel technology. The company's plant-based technology has revolutionized the current standard by stopping bleeding in seconds. The company's current and future product lines target trauma care, biosurgery, and animal health. Cresilon's mission is to save lives. For more information about Cresilon, which was named to Fast Company's annual list of the World's Most Innovative Companies of 2024, ranking No. 1 in the medical devices category, visit www.cresilon.com.

SOURCE Cresilon